Valentis News (NASDAQ:VLTS)
| Latest Valentis News Headlines | | Date | Time | Source | | | 05/17/2007 | 5:20PM | PRNUS | Valentis Receives NASDAQ Delisting Notice
BURLINGAME, Calif., May 17 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it has received notification from The Nasdaq Stock Market that its securities will be delisted from the Nasdaq Capital Market at the opening of business on May 21, 2007. The Nasdaq delisting notice was based upon... More...>> |
| 05/15/2007 | 4:40PM | PRNUS | Valentis Announces Third Quarter Fiscal 2007 Financial Results and Provides Listing Update
BURLINGAME, Calif., May 15 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) today announced financial results for its third fiscal quarter ended March 31, 2007.
Valentis reported a net income for the three months ended March 31, 2007 of $80,000, or $0.005 per basic and diluted share, on revenue of $231,000, compared... More...>> |
| 02/27/2007 | 4:15PM | PRNUS | Valentis Receives Nasdaq Additional Staff Determination
BURLINGAME, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today, as expected, that it received a letter on February 21, 2007 from the Listing Qualifications Department of the Nasdaq Stock Market formally notifying Valentis that it did not regain compliance with the minimum bid price... More...>> |
| 02/14/2007 | 4:15PM | PRNUS | Valentis Announces Second Quarter Fiscal 2007 Financial Results
BURLINGAME, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) today announced financial results for its second fiscal quarter ended December 31, 2006.
Valentis reported a net loss for the three months ended December 31, 2006 of $637,000, or $0.04 per basic and diluted share, on revenue of $260,000... More...>> |
| 02/07/2007 | 2:05PM | PRNUS | Valentis, Inc. and Urigen N.A., Inc. Announce the Filing of a Registration Statement Relating to Their Proposed Merger Transacti
BURLINGAME, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Urigen N.A., Inc., a specialty pharmaceutical company focusing on urological disorders, and Valentis, Inc. (NASDAQ:VLTS) today announced that in connection with their proposed merger transaction, a registration statement on Form S-4 was filed by Valentis on February... More...>> |
| 01/11/2007 | 4:15PM | PRNUS | Valentis Receives Nasdaq Delisting Notice and Intends to Appeal Determination
BURLINGAME, Calif., Jan. 11 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it received a letter on January 8, 2007 from the Listing Qualifications Department of the Nasdaq Stock Market indicating that trading of Valentis' common stock on the Nasdaq Capital Market will be suspended at the... More...>> |
| 11/28/2006 | 4:15PM | PRNUS | Valentis Provides Nasdaq Update
BURLINGAME, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it received a letter on November 21, 2006 from the Listing Qualifications Department of the Nasdaq Stock Market indicating that Valentis is not in compliance with Nasdaq Marketplace Rule 4310(c)(2)(B) because Valentis... More...>> |
| 11/14/2006 | 4:05PM | PRNUS | Valentis Announces First Quarter Fiscal 2007 Financial Results
BURLINGAME, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) today announced financial results for its first fiscal quarter ended September 30, 2006.
Valentis reported a net loss for the quarter ended September 30, 2006 of $2.1 million, or $0.13 per basic and diluted share, on revenue of $80,000... More...>> |
| 10/31/2006 | 6:30AM | PRNUS | Vical Acquires Angiogenesis and Poloxamer Patents from Valentis
SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- Vical Incorporated (NASDAQ:VICL) announced today that it has acquired from Valentis, Inc. (NASDAQ:VLTS) certain pending patents that complement the company's existing intellectual property positions in poloxamers and angiogenesis, and licensed from Valentis non-exclusive... More...>> |
| 10/17/2006 | 5:00AM | PRNUS | Valentis Completes Sale of Assets to Inovio Biomedical Corporation
BURLINGAME, Calif., Oct. 17 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it has entered into an asset sale agreement with Inovio Biomedical Corporation pursuant to which Inovio has acquired from Valentis certain non-core technology rights and intellectual property including:
-- GeneSwitch(C... More...>> |
| 10/05/2006 | 4:15PM | PRNUS | Valentis and Urigen Announce Signing of Definitive Merger Agreement
BURLINGAME, Calif., Oct. 5 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) and Urigen N.A., Inc., a privately-held specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications, today announced the signing of a definitive merger agreement. The... More...>> |
| 09/28/2006 | 4:15PM | PRNUS | Valentis Announces Fiscal 2006 Financial Results
BURLINGAME, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) today announced fiscal 2006 financial results for the fourth quarter and fiscal year ended June 30, 2006.
Valentis reported a net loss for the year ended June 30, 2006 of $15.3 million, or $0.99 per basic and diluted share, on revenue... More...>> |
| 08/25/2006 | 8:00PM | PRNUS | Valentis Provides Nasdaq Update
BURLINGAME, Calif., Aug. 25 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it received a Nasdaq Staff Deficiency Letter on August 23, 2006 indicating that the Company fails to comply with the minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4). Therefore... More...>> |
| 08/07/2006 | 4:15PM | PRNUS | Valentis Provides Corporate Update
BURLINGAME, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it has entered an asset sale agreement with Cobra Biologics Ltd for certain biomanufacturing rights and intellectual property. Financial terms of the sale were not disclosed but the transaction includes a one-time... More...>> |
| 07/11/2006 | 7:00AM | PRNUS | Valentis Announces Results of VLTS 934 Phase IIb Trial
BURLINGAME, Calif., July 11 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in peripheral arterial disease (PAD). The primary efficacy endpoint... More...>> |
| 05/12/2006 | 4:15PM | PRNUS | Valentis Announces Third Quarter Fiscal 2006 Financial Results
BURLINGAME, Calif., May 12 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) today announced results for its third fiscal quarter ended March 31, 2006.
Valentis reported a net loss for the three months ended March 31, 2006 of $4.9 million, or $0.32 per basic and diluted share, on revenue of $114,000, compared... More...>> |
| 03/22/2006 | 4:00AM | PRNUS | Valentis Announces - Completion of Private Placement
BURLINGAME, Calif., March 22 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced yesterday that it had completed a private placement of approximately 2.1 million shares of the Company's common stock and warrants to purchase up to approximately 1.1 million additional shares of the Company's common stock... More...>> |
| 03/21/2006 | 7:15PM | PRNUS | Valentis Announces Completion of Private Placement
BURLINGAME, Calif., March 21 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it had completed a private placement of approximately 2.1 million shares of the Company's common stock and warrants to purchase up to approximately 1.1 million additional shares of the Company's common stock at $2.50... More...>> |
| 02/14/2006 | 1:00AM | PRNUS | Valentis Announces Second Quarter Fiscal 2006 Financial Results
BURLINGAME, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) today announced results for its second fiscal quarter ended December 31, 2005.
Valentis reported a net loss for the three months ended December 31, 2005 of $3.9 million, or $0.26 per basic and diluted share, on revenue of $146,000, compared... More...>> |
| 02/13/2006 | 1:00AM | PRNUS | Valentis Completes Patient Dosing on Schedule for Phase IIb Trial of VLTS 934
BURLINGAME, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Valentis, Inc. (NASDAQ:VLTS) announced today that it has completed the dosing on schedule in its VLTS 934 Phase IIb trial for the treatment of patients suffering with peripheral arterial disease (PAD). The efficacy results are on course for July 2006.
The 140 patient... More...>> |
|
|
|